Recombinant human erythropoietin therapy in children maintained by haemodialysis

Susan P A Rigden, Giovanni Montini, Max Morris, Kenneth G A Clark, George B. Haycock, Cyril Chantler, Ronald C. Hill

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Six children (aged 3 years 11 months to 15 years 9 months) with end-stage renal failure and anaemia (mean haemoglobin 7.1 g/dl, range 6.3-7.7 g/dl) on thrice-weekly haemodialysis were treated with recombinant human erythropoietin (rHuEPO), given as an intravenous bolus in an escalating dose regime after dialysis. All responded with an increase in reticulocyte count and haemoglobin concentration in a mean time of 11 weeks (range 9-13 weeks) and at a dose of 100 or 150 units/kg thrice weekly. The dose of rHuEPO was then adjusted to maintain the haemoglobin concentration within the lower half of the normal range for the child's age and sex. The mean haemoglobin after 12 weeks treatment was 10.9 g/dl (range 8.5-12.1 g/dl) and after 24 weeks, 10.5 g/dl (range 7.9-13.3 g/dl). Four chidlren had no further need for blood transfusion and are thus no longer at risk of blood-borne infection, iron overload and sensitisation to HLA histocompatibility antigens. Serum ferritin fell in the three patients with evidence of iron overload; the three with low or normal iron stores at the onset of treatment maintained erythropoiesis with oral iron supplementation. HLA antibodies decreased in all patients. The only serious complication encountered was thrombosis of vascular access in one child. No child became seriously hypertensive or developed cerebral symptoms. The benefits of rHuEPO therapy for children with end-stage renal failure are potentially considerable and with careful monitoring, the risks low.

Original languageEnglish
Pages (from-to)618-622
Number of pages5
JournalPediatric Nephrology
Volume4
Issue number6
DOIs
Publication statusPublished - Nov 1990

Fingerprint

Erythropoietin
Renal Dialysis
Hemoglobins
Iron Overload
Chronic Kidney Failure
Iron
Reticulocyte Count
Therapeutics
Histocompatibility Antigens
Erythropoiesis
Ferritins
HLA Antigens
Blood Transfusion
Blood Vessels
Anemia
Dialysis
Reference Values
Thrombosis
Antibodies
Infection

Keywords

  • Anaemia
  • End-stage renal failure
  • Haemodialysis
  • HLA antibodies
  • Iron overload
  • Recombinant human erythropoietin

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Nephrology

Cite this

Rigden, S. P. A., Montini, G., Morris, M., Clark, K. G. A., Haycock, G. B., Chantler, C., & Hill, R. C. (1990). Recombinant human erythropoietin therapy in children maintained by haemodialysis. Pediatric Nephrology, 4(6), 618-622. https://doi.org/10.1007/BF00858637

Recombinant human erythropoietin therapy in children maintained by haemodialysis. / Rigden, Susan P A; Montini, Giovanni; Morris, Max; Clark, Kenneth G A; Haycock, George B.; Chantler, Cyril; Hill, Ronald C.

In: Pediatric Nephrology, Vol. 4, No. 6, 11.1990, p. 618-622.

Research output: Contribution to journalArticle

Rigden, SPA, Montini, G, Morris, M, Clark, KGA, Haycock, GB, Chantler, C & Hill, RC 1990, 'Recombinant human erythropoietin therapy in children maintained by haemodialysis', Pediatric Nephrology, vol. 4, no. 6, pp. 618-622. https://doi.org/10.1007/BF00858637
Rigden, Susan P A ; Montini, Giovanni ; Morris, Max ; Clark, Kenneth G A ; Haycock, George B. ; Chantler, Cyril ; Hill, Ronald C. / Recombinant human erythropoietin therapy in children maintained by haemodialysis. In: Pediatric Nephrology. 1990 ; Vol. 4, No. 6. pp. 618-622.
@article{58612063985647b49fbfca78bb006a57,
title = "Recombinant human erythropoietin therapy in children maintained by haemodialysis",
abstract = "Six children (aged 3 years 11 months to 15 years 9 months) with end-stage renal failure and anaemia (mean haemoglobin 7.1 g/dl, range 6.3-7.7 g/dl) on thrice-weekly haemodialysis were treated with recombinant human erythropoietin (rHuEPO), given as an intravenous bolus in an escalating dose regime after dialysis. All responded with an increase in reticulocyte count and haemoglobin concentration in a mean time of 11 weeks (range 9-13 weeks) and at a dose of 100 or 150 units/kg thrice weekly. The dose of rHuEPO was then adjusted to maintain the haemoglobin concentration within the lower half of the normal range for the child's age and sex. The mean haemoglobin after 12 weeks treatment was 10.9 g/dl (range 8.5-12.1 g/dl) and after 24 weeks, 10.5 g/dl (range 7.9-13.3 g/dl). Four chidlren had no further need for blood transfusion and are thus no longer at risk of blood-borne infection, iron overload and sensitisation to HLA histocompatibility antigens. Serum ferritin fell in the three patients with evidence of iron overload; the three with low or normal iron stores at the onset of treatment maintained erythropoiesis with oral iron supplementation. HLA antibodies decreased in all patients. The only serious complication encountered was thrombosis of vascular access in one child. No child became seriously hypertensive or developed cerebral symptoms. The benefits of rHuEPO therapy for children with end-stage renal failure are potentially considerable and with careful monitoring, the risks low.",
keywords = "Anaemia, End-stage renal failure, Haemodialysis, HLA antibodies, Iron overload, Recombinant human erythropoietin",
author = "Rigden, {Susan P A} and Giovanni Montini and Max Morris and Clark, {Kenneth G A} and Haycock, {George B.} and Cyril Chantler and Hill, {Ronald C.}",
year = "1990",
month = "11",
doi = "10.1007/BF00858637",
language = "English",
volume = "4",
pages = "618--622",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Recombinant human erythropoietin therapy in children maintained by haemodialysis

AU - Rigden, Susan P A

AU - Montini, Giovanni

AU - Morris, Max

AU - Clark, Kenneth G A

AU - Haycock, George B.

AU - Chantler, Cyril

AU - Hill, Ronald C.

PY - 1990/11

Y1 - 1990/11

N2 - Six children (aged 3 years 11 months to 15 years 9 months) with end-stage renal failure and anaemia (mean haemoglobin 7.1 g/dl, range 6.3-7.7 g/dl) on thrice-weekly haemodialysis were treated with recombinant human erythropoietin (rHuEPO), given as an intravenous bolus in an escalating dose regime after dialysis. All responded with an increase in reticulocyte count and haemoglobin concentration in a mean time of 11 weeks (range 9-13 weeks) and at a dose of 100 or 150 units/kg thrice weekly. The dose of rHuEPO was then adjusted to maintain the haemoglobin concentration within the lower half of the normal range for the child's age and sex. The mean haemoglobin after 12 weeks treatment was 10.9 g/dl (range 8.5-12.1 g/dl) and after 24 weeks, 10.5 g/dl (range 7.9-13.3 g/dl). Four chidlren had no further need for blood transfusion and are thus no longer at risk of blood-borne infection, iron overload and sensitisation to HLA histocompatibility antigens. Serum ferritin fell in the three patients with evidence of iron overload; the three with low or normal iron stores at the onset of treatment maintained erythropoiesis with oral iron supplementation. HLA antibodies decreased in all patients. The only serious complication encountered was thrombosis of vascular access in one child. No child became seriously hypertensive or developed cerebral symptoms. The benefits of rHuEPO therapy for children with end-stage renal failure are potentially considerable and with careful monitoring, the risks low.

AB - Six children (aged 3 years 11 months to 15 years 9 months) with end-stage renal failure and anaemia (mean haemoglobin 7.1 g/dl, range 6.3-7.7 g/dl) on thrice-weekly haemodialysis were treated with recombinant human erythropoietin (rHuEPO), given as an intravenous bolus in an escalating dose regime after dialysis. All responded with an increase in reticulocyte count and haemoglobin concentration in a mean time of 11 weeks (range 9-13 weeks) and at a dose of 100 or 150 units/kg thrice weekly. The dose of rHuEPO was then adjusted to maintain the haemoglobin concentration within the lower half of the normal range for the child's age and sex. The mean haemoglobin after 12 weeks treatment was 10.9 g/dl (range 8.5-12.1 g/dl) and after 24 weeks, 10.5 g/dl (range 7.9-13.3 g/dl). Four chidlren had no further need for blood transfusion and are thus no longer at risk of blood-borne infection, iron overload and sensitisation to HLA histocompatibility antigens. Serum ferritin fell in the three patients with evidence of iron overload; the three with low or normal iron stores at the onset of treatment maintained erythropoiesis with oral iron supplementation. HLA antibodies decreased in all patients. The only serious complication encountered was thrombosis of vascular access in one child. No child became seriously hypertensive or developed cerebral symptoms. The benefits of rHuEPO therapy for children with end-stage renal failure are potentially considerable and with careful monitoring, the risks low.

KW - Anaemia

KW - End-stage renal failure

KW - Haemodialysis

KW - HLA antibodies

KW - Iron overload

KW - Recombinant human erythropoietin

UR - http://www.scopus.com/inward/record.url?scp=0025637725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025637725&partnerID=8YFLogxK

U2 - 10.1007/BF00858637

DO - 10.1007/BF00858637

M3 - Article

C2 - 2088464

AN - SCOPUS:0025637725

VL - 4

SP - 618

EP - 622

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 6

ER -